Summary
Labcorp Holdings Inc reported an insider sale by a senior finance officer and disclosed developments in both its results and diagnostic technology adoption. Peter J. Wilkinson, the company's SVP and Chief Accounting Officer, sold 666 shares of Labcorp common stock on February 19, 2026, under a Rule 10b5-1 trading plan. The shares were sold at $277.94 each for a total transaction value of $185,108. After the sale, Wilkinson directly holds 1,852.2194 shares.
Insider transaction details
The sale of 666 shares was executed at $277.94 per share on the February 19 trade date, producing proceeds of $185,108. The disposition was reported on a Form 4 filing with the Securities and Exchange Commission and was conducted pursuant to an established Rule 10b5-1 trading arrangement. Following this trade, Wilkinson's direct ownership stands at 1,852.2194 shares of Labcorp common stock.
Market context and valuation note
Labcorp's stock was trading at $282.67 at the time of the report, representing a 12.67% gain year-to-date. InvestingPro analysis cited in company commentary characterizes the shares as remaining undervalued. InvestingPro also provides Fair Value estimates and additional ProTips associated with the company, which is described as a $23.24 billion healthcare concern.
Recent financial performance
Labcorp released fourth-quarter 2025 results showing a mixed set of outcomes. The company posted earnings per share of $4.07, outperforming the consensus estimate of $3.93. Revenue for the quarter, however, came in at $3.52 billion versus an anticipated $3.56 billion, a shortfall relative to expectations.
Technology partnership and operational impact
Separately, Labcorp announced an expanded collaboration with PathAI to deploy the AISight Dx digital pathology platform across its national network of anatomic pathology laboratories and hospital collaborations. The platform is described as FDA-cleared and cloud-based, enabling pathologists to manage slides digitally and to leverage artificial intelligence as an aid in diagnostic workflows. Labcorp said the technology will enhance case management, slide review, collaboration, and annotation within its anatomic pathology labs.
What this signals
These items - the insider sale, the mixed quarterly results, and the broader rollout of a digital pathology platform - together reflect Labcorp's parallel paths of managing near-term financial expectations while advancing technology integration in its diagnostic operations.